Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)
Paul Brennan(University of Dundee), Stuart J. Forbes(MRC Centre for Regenerative Medicine), Neil McGowan(Scottish National Blood Transfusion Service), Chloe Pass(Scottish National Blood Transfusion Service), Neil Lachlan(Glasgow Royal Infirmary), Alasdair R. Fraser(Scottish National Blood Transfusion Service), Scott Semple(University of Edinburgh), Mark T. Macmillan(MRC Centre for Regenerative Medicine), Francesca Moroni(Aberdeen Royal Infirmary), Catriona Graham(University of Edinburgh), Thomas Manship(NHS Lothian), Alison Glover(Scottish National Blood Transfusion Service), Jonathan Fallowfield(Centre for Inflammation Research), Marc L. Turner(Scottish National Blood Transfusion Service), John Campbell(Scottish National Blood Transfusion Service), David M. Morris(University of Edinburgh), John Dillon(Mayo Clinic)
Cited by 45
Related Papers
MAIT cells are activated during human viral infections
|Nature Communications|2016|520
Hepatic progenitor cells of biliary origin with liver repopulation capacity
|Nature Cell Biology|2015|500
Cell therapy for liver disease: From liver transplantation to cell factory
|Journal of Hepatology|2015|344
Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids
|Cell stem cell|2021|311
Liver regeneration and inflammation: from fundamental science to clinical applications
|Nature Reviews Molecular Cell Biology|2021|289